Keros Therapeutics (KROS) stock surges 22% amid strategic review for sale and the adoption of a poison pill to protect ...

NerdWallet’s comprehensive review process evaluates and rates the largest ... Note that a broker may score highly for the stock trading platforms, tools or research it offers, but low for ...

Let’s take a look at how data & business process services stocks fared in Q4 ... with a significant miss of analysts’ full-year EPS guidance estimates. The stock is down 1.8% since reporting and ...

Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of ProcessLEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros ...

This plan aims to ensure fair participation in the strategic review process and prevent any group ... of 10% or more of Keros' outstanding common stock without board approval.